Thalassemia Major Clinical Trial
Official title:
Quantification of Diffuse Myocardial Iron Overload Related Interstitial Fibrosis With Cardiac Magnetic Resonance Imaging in Patients With Transfusion-Dependent Anemias
Cardiac failure is the major cause of death in patients with thalassemia and chronic blood transfusion-related iron overload. The treatment of thalassemia has been revolutionized over the past decade with the implementation of cardiac MRI based assessment of iron overload. This has enabled detection of cardiac iron overload prior to symptomatic heart failure and now allows for timely therapy which has resulted in a substantial decrease in mortality. However, currently implemented MR imaging techniques assess for iron content only and not for iron related diffuse fibrosis which play a role in iron related heart failure. Histopathologic studies indicate that patients with iron overload have diffuse interstitial fibrosis. Quantitative MR techniques have shown that patients with various cardiomyopathies demonstrate diffuse myocardial fibrosis and that these changes correlate with changes in cardiac function. The investigators propose that quantitative cardiac MRI for assessment of diffuse myocardial fibrosis can further improve our ability to detect early damage to the myocardium and prevent morbidity and mortality from cardiac iron overload. Detection of fibrosis in patients with thalassemia may allow for earlier identification of cardiomyopathy when compared to other techniques in clinical use including T2* analysis. Identification of fibrosis could affect patient management as it would allow for tailoring of iron chelation therapy and may lead to better understanding of the disease processes contributing to heart failure and arrhythmia in these patients.
Cardiac failure is the major cause of death in patients with transfusion-related iron
overload. Histopathologic studies indicate that patients with myocardial siderosis have
diffuse interstitial fibrosis. Cardiac MR assessment of the extracellular volume (ECV)
fraction in other disease processes has been shown to accurately characterize diffuse
myocardial fibrosis and to correlate with changes in diastolic function. No prior studies
have assessed for diffuse interstitial myocardial fibrosis in patients with iron overload
utilizing the proposed imaging techniques.
In this study, the investigators will assess the presence and extent of interstitial
fibrosis in patients with transfusion-dependent anemias using cardiac MR techniques of T1
mapping and determination of ECV fraction. ECV values will be correlated with the severity
of myocardial iron deposition determined by multi-echo T2*-weighted imaging, systolic
ventricular function as determined by cardiac MR and diastolic function assessed by
echocardiography. The investigators will recruit 35 patients with transfusion-related iron
overload. Ten age-matched healthy subjects will be included as controls, to establish
baseline values of myocardial T1 and ECV values. A modified Look-Locker with inversion
recovery (MOLLI) sequence will be used to determine T1 values pre-, and post-administration
of a gadolinium-based contrast agent (GBCA) at 1.5 Tesla. Calculated ECV values will be
compared between iron-overload subjects and healthy controls, and will be correlated with
left ventricular ejection fraction, measures of diastolic dysfunction and T2* values.
Detection of myocardial fibrosis in patients with iron overload would allow for improved
prognostication and risk stratification. Elucidation of the relationship between myocardial
fibrosis and myocardial iron deposition as well as cardiac functional parameters would
provide valuable mechanistic insights and improved pathophysiological understanding of the
disease. The results of the proposed study have the potential to significantly impact
patient management including recommendations for earlier or more aggressive chelation
therapy based on changes in ECV values.
;
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02559648 -
Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis
|
Phase 2 | |
Recruiting |
NCT02126046 -
Unrelated Umbilical Cord Blood Following HLA-haploidentical Hematopoietic Stem Cell Transplantation in Patients With β-thalassemia Major
|
N/A | |
Completed |
NCT01125254 -
Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major
|
Phase 2/Phase 3 | |
Terminated |
NCT00034528 -
Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia
|
Phase 2 | |
Completed |
NCT00733811 -
Efficacy Study of the Use of Sequential DFP-DFO Versus DFP
|
Phase 4 | |
Enrolling by invitation |
NCT02986698 -
In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM)
|
Phase 1 | |
Not yet recruiting |
NCT06026839 -
Longitudinal Study on the QoL of Pediatric Patients After HSCT and Its Influencing Factors
|
||
Terminated |
NCT00007072 -
Phase II Study of Azacitidine and Phenylbutyrate in Patients With Thalassemia Major
|
Phase 2 | |
Completed |
NCT04292314 -
Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia
|
Phase 2/Phase 3 | |
Completed |
NCT02049450 -
Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.
|
Phase 2 | |
Active, not recruiting |
NCT04523376 -
Pilot Study PBSCT With TCRab Depletion For Hemoglobinopathies
|
N/A | |
Completed |
NCT03992001 -
Impact of the Preparation Method of Red Cell Concentrates on Transfusion Indices in Thalassemic Patients
|
Phase 4 | |
Not yet recruiting |
NCT05777733 -
NAC Effect on Iron Overload and Blood Transfusion in β-thalassemia Major
|
Phase 1 | |
Completed |
NCT01241357 -
High-Tc Susceptometer to Monitor Transfusional Iron Overload
|
Phase 2 | |
Completed |
NCT00749515 -
Pilot Study for Patients With Poor Response to Deferasirox
|
Phase 4 | |
Completed |
NCT04260516 -
The Effect of N-acetylcysteine on Oxidative Stress Status and Iron Overload in Thalassemia Major
|
Phase 1 | |
Recruiting |
NCT02307786 -
Long Term Outcomes in β Thalassemia Major
|
N/A | |
Not yet recruiting |
NCT01323608 -
The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study
|
Phase 4 | |
Completed |
NCT00005893 -
Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders
|
N/A | |
Recruiting |
NCT06137079 -
"Iron Overload and Endocrinological Diseases"
|